61
Participants
Start Date
April 1, 2022
Primary Completion Date
June 30, 2022
Study Completion Date
June 30, 2022
Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.
Blood test to value the antibody response to vaccination
Policlinico Tor Vergata, Roma
University of Rome Tor Vergata
OTHER